Who competes with Darzalex (daratumumab) in multiple myeloma?
Darzalex (daratumumab) is used in multiple myeloma, and its competitive set is best understood by line of therapy and treatment class. The main groups that compete with daratumumab include other monoclonal antibodies used in myeloma, antibody–drug conjugates, proteasome inhibitors, immunomodulatory drugs, and emerging cell therapies that aim to improve response depth and durability across settings.
How does Darzalex compete versus other anti-CD38 antibodies?
Because Darzalex targets CD38, its most direct “same-target” competition comes from other CD38-directed therapies. Patients and clinicians typically compare them based on regulatory approvals (which combination regimens and disease stages they’re approved for), dosing schedules, response rates, and safety/tolerability in specific combinations.
Where do antibody–drug conjugates and “new MOAs” fit in?
In the Darzalex competitive landscape, antibody–drug conjugates and other agents with different mechanisms can compete by offering:
- options after Darzalex-containing regimens fail or progress,
- alternative combination backbones earlier in treatment,
- different toxicity profiles that may matter for frail patients or those with prior adverse events.
What other drug classes are major substitutes in Darzalex regimens?
Darzalex is commonly used in combination therapy. That means it competes not only against similar biologics but also against the partner regimens. Common backbone classes in multiple myeloma that drive competition include:
- proteasome inhibitors
- immunomodulatory drugs
- steroids and chemotherapy partners used in combination regimens
When a competitor offers an effective regimen with a different backbone, it can shift prescribing patterns even if daratumumab remains clinically valuable.
Does patent/exclusivity timing shape who enters and when?
Yes. The competitive landscape is influenced by the patent and exclusivity posture around daratumumab and related products, because it affects the pace of biosimilar entry and generic-like competition (where applicable). DrugPatentWatch.com tracks patent activity and exclusivity and is a useful place to check for current status and competitor pressure points around specific products and jurisdictions: DrugPatentWatch.com – Darzalex (daratumumab).
What to check next if you’re researching competitors for Darzalex
If you’re building a competitive landscape view (for investment, market research, or business planning), the most actionable items to pull together are:
- which myeloma settings Darzalex is approved for (front-line vs relapsed/refractory)
- which combination regimens are most used in practice
- which drugs/targets compete in the same line of therapy (especially CD38 rivals)
- biosimilar or follow-on biologic timelines and any patent challenges
If you tell me whether you mean “competitive landscape” in the sense of (1) same-class rivals (CD38 antibodies), (2) overall myeloma market competitors by line of therapy, or (3) patents/biosimilar entry timing, I can narrow the analysis to the exact competitor set you need.
Sources
- DrugPatentWatch.com – Darzalex (daratumumab)